Dr. Katherine Grantz is a Senior Investigator with tenure in the Epidemiology Branch, DiPHR, DIR, NICHD, NIH and Senior Maternal-Fetal Medicine Attending at MedStar Washington Hospital Center and Professor of Obstetrics and Gynecology at Georgetown University Hospital. She leads a research program on clinical management of pregnancy complications, including aberrant fetal growth, when to deliver a high-risk pregnancy, and labor and delivery management. Findings from her research have informed over 51 national and international clinical guidelines with evidence-based practice recommendations. An expert in the field of fetal growth, Dr. Grantz and her team were responsible for a multidisciplinary effort that generated fetal growth percentile charts in a diverse U.S population for clinical practice. She led development of a first ever fetal growth velocity calculator for clinical use as well as development of twin fetal growth percentile charts. Her work is addressing the clinical challenge of differentiating constitutionally small-for-gestational-age from fetal growth restriction that is associated with increased morbidity and mortality. An emerging area uses 3-dimensional (3D) ultrasound that provides more detail than the standard 2D ultrasound in determining fetal fat and lean tissue volumes. Dr. Grantz’s group is among the first to have accumulated the largest collection of fetal 3D volumes from a heterogeneouspregnancy cohort with repeat ultrasounds spanning the length of gestation. Detection of fetal volume and body composition changes in fetuses that are growth restricted or in complicated pregnancies including gestational diabetes and preeclampsia has potential to inform clinical management, such as increased antenatal monitoring to prevent stillbirth or changes in maternal glucose control to prevent excess fetal fat accumulation. Her team is also addressing labor and delivery management to prevent medically unnecessary cesarean deliveries, an issue declared as a national priority as cesarean delivery is a risk factor for severe maternal morbidity and mortality. More recently, she led a multi-center randomized clinical trial to determine the optimal timing of delivery for gestational diabetes complicated pregnancies to prevent neonatal complications.